Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Invivyd, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $39.4 million, EPS Basic and diluted net loss per share was $0.36.
- Period
- quarter ended September 30, 2023
- Net income
- Net loss was $39.4 million
- EPS
- Basic and diluted net loss per share was $0.36
- Result
- reported results
Exact text from the filing
Third Quarter 2023 Financial Results: • Cash position: Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023. • Cash runway: Based on current operating plans, Invivyd continues to expect its existing total cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into the fourth quarter of 2024, excluding potential contribution of commercial product revenue if a mAb candidate is authorized or approved. • Research & development (R&D) expenses (including in-process research & development): R&D expenses were $30.2 million for the quarter ended September 30, 2023, compared to $34.1 million for the comparable period of 2022. The decrease is primarily attributable to higher clinical trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials, partially offset by clinical trial costs associated w
View on SEC.gov